Literature DB >> 30707896

High levels of RAI3 expression is linked to shortened survival in esophageal cancer patients.

Alexander Tarek El Gammal1, Nathaniel Melling2, Matthias Reeh3, Florian Gebauer4, Oliver Mann5, Daniel Perez6, Maximillian Bockhorn7, Kai Bachmann8, Jakob Robert Izbicki9, Katharina Grupp10.   

Abstract

Expression of the retinoic acid-induced protein 3 (RAI3) has been suggested to predict clinical outcome in a variety of malignancies. However, its role in esophageal cancers remains unclear. Immunohistochemical RAI3 staining was analyzed on tissue microarrays containing 359 esophageal adenocarcinomas (EAC) and 254 esophageal squamous cell carcinomas (ESCC). RAI3 immunostaining was typically absent or weakly detectable in the membranes in benign esophageal tissues. RAI3 staining was higher in malignant than in benign esophagus epithelium. High-levels of RAI3 staining were found in 79.2% of interpretable EACs and 55.9% of ESCCs. In EACs, strong RAI3 staining was associated with advanced pathological tumor stage (p < .0001), high UICC stage (p < .0001), high tumor grade (p = .0133), and positive lymph nodal status (p = .0002). Additionally, high RAI3 staining predicted shortened overall survival of EAC and ESCC patients (p = .0298 and p = .0227). RAI3 overexpression is associated with poor prognosis in esophageal cancers. We propose that RAI3 overexpression might play a biologically relevant role of RAI3 in esophageal cancers.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Esophageal adenocarcinoma; Esophageal cancer; Esophageal squamous cell carcinoma; Immunohistochemistry; RAI3; TMA

Mesh:

Substances:

Year:  2019        PMID: 30707896     DOI: 10.1016/j.yexmp.2019.01.013

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  1 in total

1.  Prognostic and clinicopathological significance of GPRC5A in various cancers: A systematic review and meta-analysis.

Authors:  Lu Dai; Xiao Jin; Zheng Liu
Journal:  PLoS One       Date:  2021-03-31       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.